Zydus Lifesciences Limited has announced a definitive agreement to acquire Assertio Holdings, Inc. for USD 166.4 million in an all-cash deal. Valued at USD 23.50 per share, this strategic acquisition provides Zydus with an established U.S. specialty oncology commercial platform. The deal includes the rights to ROLVEDON®, a key treatment for chemotherapy-induced neutropenia, and leverages Assertio’s existing network of over 170 community oncology accounts to expand Zydus’s footprint in the U.S. market.
Strategic Rationale and Oncology Expansion
The acquisition of Assertio marks a significant milestone in Zydus’s long-term strategy to build a global, differentiated specialty business. By securing Assertio’s U.S. oncology commercial platform, Zydus gains immediate access to a specialized infrastructure and established professional relationships. This platform will serve as a cornerstone for scaling the company’s broader oncology specialty portfolio in the United States.
Product Portfolio and Financials
At the center of this transaction is ROLVEDON® (eflapegrastim), a USFDA-approved, long-acting G-CSF biologic used for the prevention of febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy. Assertio has demonstrated steady commercial performance with this asset, reporting an adjusted turnover of USD 68.23 million in 2025 and USD 60.09 million in 2024. The company’s buy-and-bill infrastructure is expected to provide a ready-made base for Zydus’s future growth in this therapeutic segment.
Transaction Details and Expected Timeline
The deal is structured as an all-cash tender offer followed by a merger, through which Assertio will become a part of the Zydus group and be delisted from the Nasdaq exchange. The total consideration is approximately USD 166.4 million on a fully-diluted basis. Following the initial tender, a second-step merger will ensure Zydus acquires 100% of outstanding shares. Both companies anticipate the transaction will close within the 2026-27 financial year, subject to customary closing conditions and regulatory approvals.
Source: BSE
